Myriad Genetics (MYGN) reported 40% year-over-year growth in volumes of disease-specific panels sold in fiscal 2017.
On November 9, 2017, Stryker (SYK) announced FDA approval for the Neuroform Atlas Stent System, which is approved for marketing under an HDE.
Stryker stock has registered slightly volatile activity in the past few months. However, the stock largely remains on a bullish trajectory.
On November 28, 2017, Howmedica Osteonics, an orthopedics subsidiary of Stryker (SYK) and Zimmer Biomet Holdings (ZBH), settled a trade secret case.
As of November 30, 2017, in a Reuters survey of 27 investment research companies, ~63% or 17 firms recommended Stryker stock as a “buy.”
In the first quarter of 2018, Myriad Genetics’ (MYGN) Prolaris reported revenues close to $2.9 million, which is flat growth on a year-over-year (or YoY) basis.
Myriad Genetics (MYGN) recently launched personalized medicine tool, riskScore, which uses clinical and genome markers to assess a woman’s lifetime risk for breast cancer.
In the first quarter of fiscal 2018, Myriad Genetics (MYGN) launched riskScore, a tool within the myRisk Hereditary Cancer test that is considered to be a major innovation in hereditary cancer testing.
On March 27, 2017, the FDA also approved BRACAnalysis CDX test as a complementary diagnostic test to be used with ovarian cancer maintenance therapy Tesaro’s (TSRO) Zejula (miraparib).
Myriad Genetics (MYGN) expects to attain a penetration level of 4% in the companion diagnostics segment by 2020.
Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.
In October 2017, Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that their Phase 3 dupilumab study had met its primary and secondary endpoints. The study was conducted to evaluate the safety and…
In 3Q17, Regeneron Pharmaceuticals’ (REGN) Eylea generated revenue of $953 million, which reflected ~12% growth YoY (year-over-year) and 4% growth QoQ (quarter-over-quarter). In the first nine months of 2017, Eylea saw revenue…
In 3Q17, Regeneron Pharmaceuticals (REGN) generated revenue of $1.5 billion, which reflected ~23% growth year-over-year and ~2% growth quarter-over-quarter.
CVS is paying more than 11 times the trailing 12-month EBITDA for Aetna.
CVS Health (CVS) announced its intention to acquire Aetna (AET) for $207 per share, or $69 billion.
CVS Health (CVS), America’s largest pharmacy chain, announced a $69 billion deal to purchase Aetna (AET), the country’s third-largest insurance company, on December 3, 2017.
Wall Street analysts estimate that GlaxoSmithKline’s (GSK) top line could fall 0.8% to ~7.5 billion pounds in 4Q17.
GSK’s Consumer Healthcare business reported revenues of ~2.0 billion pounds during 3Q17, reflecting 5.0% growth in revenues compared to ~1.9 billion pounds during 3Q16.
GlaxoSmithKline’s (GSK) Vaccines business reported revenues of ~1.7 billion pounds during 3Q17, reflecting 5.0% growth in revenues compared to 3Q16.